Japanese Pharmas Hit By Strong Yen: Japanese Pharma Earnings Roundup
This article was originally published in PharmAsia News
Executive Summary
TOKYO - As expected, top Japanese pharmaceutical players have reported lackluster April-June earnings as they struggled under the strong yen's weight, with three leading firms reiterating efforts to expedite launching products now in the pipelines
You may also be interested in...
Is It Better To Be First Or Best? Daiichi Sankyo Shifts R&D Priorities
TOKYO - Daiichi Sankyo's R&D leaders are optimistic about how factor Xa inhibitor edoxaban can compete in a potentially crowded market, but the company is also shifting its focus to development of first-in-class compounds, citing commercial and regulatory hurdles for follow-on, best-in-class products
Is It Better To Be First Or Best? Daiichi Sankyo Shifts R&D Priorities
TOKYO - Daiichi Sankyo's R&D leaders are optimistic about how factor Xa inhibitor edoxaban can compete in a potentially crowded market, but the company is also shifting its focus to development of first-in-class compounds, citing commercial and regulatory hurdles for follow-on, best-in-class products
Is It Better To Be First Or Best? Daiichi Sankyo Shifts R&D Priorities
Because regulators and the market have become less accepting of follow-on compounds, the Japanese pharma plans to invest in first-in-class science, pursuing best-in-class opportunities only when it sees a substantial unmet medical need.